SAN FRANCISCO--(BUSINESS WIRE)--Cancer of the uterine cervix is the second most common among women in the world, yet cervical exams and subsequent biopsies limit diagnostic accuracy to 60%. That’s why Illumigyn, a privately-held, early stage company, today introduced the Gynescope at the American Congress of Obstetricians and Gynecologists 2015 Annual Meeting (ACOG) in San Francisco. The Gynescope is a state of the art, compact imaging device for colposcopy and cervical exams. The device uses military grade “machine vision” technology to early detect cervical cancer and reduce the possibility of misdiagnosis.
“Gynescope is the result of years of research and innovation,” said Lior Greenstein, Founder and CTO of Illumigyn. “This device will be the first of its kind in the OBGYN space and we believe it will improve doctors’ abilities to accurately detect uterine cervix precancerous conditions.”
The simple to operate device comes with an array of easy to use features including auto identification of working distance, autofocus, and auto illumination control. Illumigyn’s proprietary technology also allows for a full digital suite that allows users to save, archive, retrieve and share images. By improving image accuracy and access, the Gynescope can provide the real time answers doctors need to speed up accurate diagnosis of cervical cancer.
Gynescope is has not yet been approved by the FDA and is not yet available for sale in the United States.
About Illumigyn
Illumigyn is a privately-held early stage company that has extended existing “Machine Vision” technologies from sophisticated manufacturing and military visual inspection applications into a state-of-the-art, compact imaging colposcope. The device will be used for medical applications in order to eliminate the inherent subjectivity of cervical exams. For more information please visit: http://illumigyn.com/